Stock 1801 INNOVENT BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:15 2024-04-18 am EDT 		5-day change 1st Jan Change
33.7 HKD -1.75% Intraday chart for Innovent Biologics, Inc. -9.89% -21.17%
Apr. 02 Hutchmed endometrial cancer treatment application accepted for review AN
Apr. 02 Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer
AQ
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
AQ
Hutchmed endometrial cancer treatment application accepted for review
AN
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination
MT
HSBC in special payout on Canada sale; Astra FDA win
AN
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority
MT
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
CI
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application
CI
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows
MT
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
CI
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
AQ
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%
MT
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer
CI
Nomura Adjusts Innovent Biologics’ Price Target to HK$55.31 From HK$54.51, Keeps at Buy
MT
Innovent Biologics' Phase 3 Trial for Thyroid Eye Disease Treatment Meets Primary Endpoints
MT
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease
CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials
RE
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee
CI
Innovent Biologics’ New Drug Application for Weight Management Drug Accepted by Chinese Regulator
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1801 Stock
  4. News Innovent Biologics, Inc.